ClinicalTrials.Veeva

Menu

A Study on the Effects on Glucose Regulation, Inflammation and Serum Lipids After Fish Protein Supplementation in Elderly (GRIPE)

U

University of Bergen

Status

Completed

Conditions

Aging
Inflammation
Blood Sugar; High
Muscle Weakness
Muscle Loss

Treatments

Dietary Supplement: Placebo Comparator: Control
Dietary Supplement: Blue whiting protein hydrolysate

Study type

Interventional

Funder types

Other

Identifiers

NCT03529344
2015/75

Details and patient eligibility

About

The elderly population have and increased risk of loss of both muscle mass and function and is therefore recommended a higher protein intake than the healthy adult population. These age-related changes in muscle function may be explained by chronic low-grade inflammation and insulin resistance. Despite the recommendation of a higher protein intake, little is known about how different protein sources may affect the metabolic health in this population. Analysis of amino acid composition show that fish can be a good protein source for humans. Many fish species are today used as feed ingredients, rather than a protein source for humans. A few studies conducted in humans and rats show that proteins from fish may improve glucose tolerance, reduce inflammation and improve lipid metabolism, indicating that proteins from fish may not only serve as a valuable nutrient but could also hold specific health promoting properties.

The present study will investigate the effects of a protein hydrolysate from blue whiting, a fish species normally used to produce fish meal for aquaculture industry, on glucose homeostasis, inflammation and serum lipids in elderly nursing home residents.

Full description

Participants receive 6g per day of protein hydrolysate from blue whiting as protein powder mixed with a non-caloric juice for 6 weeks.

Enrollment

24 patients

Sex

All

Ages

60+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • >60 years
  • both genders
  • nursing home resident

Exclusion criteria

  • life expectancy < 6 months
  • severe cognitive impairment
  • allergies towards fish, milk, egg
  • weight loss >5% last 3 months

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

24 participants in 2 patient groups, including a placebo group

Blue whiting protein hydrolysate
Active Comparator group
Description:
Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
Treatment:
Dietary Supplement: Blue whiting protein hydrolysate
Placebo Comparator: Control
Placebo Comparator group
Description:
Control group will receive non-caloric juice without protein supplementation
Treatment:
Dietary Supplement: Placebo Comparator: Control

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems